Cytokinetics (CYTK) FY2016 results: revenue $106 million, up 271.3% on the year
Cytokinetics Inc. (CYTK) reported revenue of $106 million for fiscal 2016, the year ended 31 December 2016, up 271.3% on the year before. Net income was $16 million, and diluted earnings per share $0.39. The figures are the company's own, from the 10-K it filed with the SEC on 6 March 2017.
Revenue
$106 million
+271.3% on the year
FY2009FY2016
Operating margin
17.6%
-130.5% a year earlier
FY2009FY2016
Net income
$16 million
FY2009FY2016
Diluted EPS
$0.39
FY2009FY2016
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Revenue
106
28.7
46.9
+271.3%
Research and development
59.9
46.4
44.4
+29.1%
Operating income
18.7
-37.4
-14.8
Operating margin
17.6%
-130.5%
-31.4%
Interest expense
2.7
0.3
0.0
+906.7%
Pre-tax income
16.5
-37.5
-14.6
Income tax
0.0
0.0
0.0
Effective tax rate
0.0%
n/a
n/a
Net income
16.5
-37.5
-14.6
Net margin
15.5%
-130.9%
-31.2%
Diluted EPS
$0.39
-$0.97
-$0.41
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Operating cash flow
37.0
4.9
-44.8
+657.4%
Capital expenditure
1.6
0.6
1.1
+184.0%
Free cash flow
35.4
4.3
-45.9
+718.9%
Free cash flow margin
33.3%
15.1%
-97.9%
Depreciation and amortisation
0.7
0.6
0.5
+25.8%
Share-based compensation
7.1
4.6
3.3
+56.5%
Diluted shares, weighted
43m
39m
36m
+9.7%
Shares outstanding at period end
41m
40m
39m
+2.7%
Balance sheet
$ million
FY2016
FY2015
FY2014
On the year
Last 8 years
Shareholders' equity
94.4
68.6
92.1
+37.6%
Debt
29.9
14.6
0.0
+104.1%
Other liabilities
45.9
32.0
40.9
+43.4%
Total liabilities and equity
170
115
133
+47.6%
Fixed assets
3.6
1.8
1.6
+107.7%
Investments
97.0
46.5
63.0
+108.5%
Cash and equivalents
66.9
65.1
20.2
+2.8%
Receivables
0.0
n/a
n/a
Other assets
2.6
1.9
48.1
+37.3%
Total assets
170
115
133
+47.6%
10-K for the year ended 31 December 2016, filed 6 March 2017: the filing.